Research Analyst Reaffirms "Buy" Rating on BAT

BusinessBAT by 2FIRSTS.ai

Nov.20.2023

Research Analyst Reaffirms "Buy" Rating on BAT

Research analysts reaffirmed a "buy" rating on British American Tobacco (LON:BATS) after its stock fell 2p (0.02 USD) to 2,518p (30.92 USD) on Wednesday.

In a research report on Wednesday, analysts reconfirmed their "buy" rating on British American Tobacco (LON:BATS). Shares of BATS declined by 2 pence (0.02 USD) to a price of 2,518 pence (30.92 USD) during midday trading on Wednesday.

References:

[1] Jefferies Financial Group Reaffirms Buy Rating for British American Tobacco (LON:BATS)

Also Read:

[1] BAT Celebrating One Year Anniversary of glo™ Smokeless Product

[2] BAT Russian Division's Ownership Transferred to Abu Dhabi

#Research #British American Tobacco (BAT)

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Calls on Retailers to Remove Illegal E-Cigarettes from Shelves, Will Send List of Legal Products to 300,000 Stores

FDA launches national retail compliance initiative to combat illegal e-cigarette sales targeting youth, issuing guidance materials to over 300k retailers.

Oct.08 by 2FIRSTS.ai

Singapore Schools Enhance Anti-E-cigarette Education with Scenario Discussions and Scientific Evidence

Singapore schools are ramping up anti-vaping education through Character and Citizenship Education (CCE) and science lessons. Classes now use scenario-based discussions—for example, a friend asking you to hide their vape during a random bag check—to help students practise refusal, empathy and seeking help safely.

Oct.22 by 2FIRSTS.ai

Tyumen Regional Parliament in Russia Reviewing Bill to Impose Total Ban on E-Cigarette Sales

Russia's Tyumen Council is considering a bill to ban e-cigarettes and vaping products, sparking concerns about potential risks.

Oct.13 by 2FIRSTS.ai

The U.S. Department of Justice and FDA seized 2.1 million e-cigarettes and 12 distributors and retailers were sued

Recently, the U.S. Department of Justice and the FDA announced a joint crackdown on illegal e-cigarettes, seizing over 2.1 million unauthorized e-cigarette products from five distributors and six retailers in seven states. The companies involved had previously received warnings from the FDA but continued to sell products without market approval. This operation was jointly carried out by multiple government departments, and civil injunction lawsuits have been filed against 12 related companies an